Alkylating Agents

Anticancer Therapeutics

Volumn , Issue , 2008, Pages 133-158

  Francisco, Ana Paula ^a   Perry, Maria De Jesus ^a   Moreira, Rui ^a   Mendes, Eduarda ^a  

^a RESEARCH INSTITUTE FOR MEDICINES IMED ULISBOA   (Portugal)

Author keywords

Alkylating agents oldest anticancer drug class; B cell chronic lymphocytic leukaemia (B CLL) and alkylating agents; Methylhydrazine derivatives; Nitrogen mustards; Nitrosoureas; Novels nitrosourea derivatives; Procarbazine monoamine oxidase (MAO) inhibitor

Indexed keywords

EID: 84889348566     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470697047.ch9     Document Type: Chapter

References (118)

1. Agarwala SS, Kirkwood JM. Temozolomide, a novel alkylating agent with activity in the central nervous system, may improve the treatment of advanced metastic melanoma. Oncologist 2000, 5, 144-51.
2. Alberts DS, Jiang C, Liu PY, Wilczynski S, Markman M, Rothenberg ML. Long-term follow-up of a phase II trial of oral altretamine for consolidation of clinical complete remission in women with stage III epithelial ovarian cancer in the Southwest Oncology Group. Int J Gynecol Cancer 2004, 14, 224-8.
3. Alexanian R, Bergsagel DE, Migliore PJ, Vaughn WK, Howe CD. Melphalan therapy for plasma cell myeloma. Blood 1968, 31, 1-10.
4. Aoki T, Takahashi JA, Ueba T, et al. Phase II study of nimustine, carboplatin, vincristine, and interferonbeta with radiotherapy for glioblastoma multiforme: experience of the Kyoto Neuro-Oncology Group. J Neurosurg 2006, 105, 385-91.
5. Arnold R, Rinke A, Schmidt Ch, Hofbauer L. Endocrine tumours of the gastrointestinal tract:Chemotherapy. Best Pract Res Clin Gastroenterol 2005, 19, 649-56.
6. Atta J, Chow KU, Weidmann E, Mitrou PS, Hoelzer D, Martin H. Dexa-BEAM as salvage therapy in patients with primary refractory aggressive non-Hodgkin lymphoma. Leuk Lymphoma 2007, 48, 349-56.
7. Avril MF, Aamdal S, Grob JJ, et al. Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study. J Clin Oncol 2004, 22, 1118-25.
8. Balcome S, Park S, Dorr DR, Hafner L, Philips L, Tretyakova N. Adenine-containing DNA-DNA cross-links of antitumor nitrogen mustards. Chem Res Toxicol 2004, 17, 950-62.
9. Balfour JA, Goa KL. Bendamustine. Drugs 2001, 61, 631-8.
10. Bauer GB, Povirk LF. Specificity and kinetics of interstrand and intrastrand bifunctional alkylation by nitrogen mustards at a G-G-C sequence. Nucl Acids Research 1997, 25, 1211-18.
11. Bergh J, Wiklund T, Erikstein B, et al. Tailored fluorouacil, epirubicin, and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer: a randomised trial. Lancet 2000, 356, 1384-91.
12. Bishop JB, Wassom JS. Toxicological review of busulfan (Myleran). Mutat Res 1986, 168, 15-45.
13. Bleehen NM, Newlands ES, Lee SM, et al. Cancer Research Campaign Phase II trial of temozolomide in metastatic melanoma. J Clin Oncol 1995, 13, 910-13.
14. Boddy AV, Yule SM. Metabolism and pharmacokinetics of oxazaphosphorines. Clin Pharmacokinet 2000, 38, 291-304.
15. Boehnke-Michaud L. Skin cancers and melanomas. In Textbook of Therapeutics: Drug and Disease Management, 6th edn, edited by Herfindal ET, Gourley DR, Williams & Wilkins, Baltimore, 1996, p 1678.
16. Bolzan AD, Bianchi MS. Genotoxicity of streptozotocin. Mutat Res 2002, 512, 121-34.
17. Bonadonna G, Viviani S, Bonfante V, Gianni A, Valagussa P. Survival in Hodgkin's disease patients - report of 25 years of experience at the Milan Cancer Institute. Eur J Cancer 2005, 41, 998-1006.
18. Busulfan BC Cancer Agency Drug. The Cancer Drug Manual©. Vancouver. Available from http://www.bccancer.bc.ca/HPI/DrugDatabase/default.htmhttp://www.bccancer.bc.ca/HPI/DrugDatabase/default.htm
19. Cairncross G, Berkey B, Shaw E, et al. Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402. J Clin Oncol 2006, 24, 2707-14.
20. Carmustine AHFS Drug information, Bethesda, MD: American Society of Health-System Pharmacists. Electronic version 2007. Available from http://www.medecinescomplete.com/. [accessed 19 July 2007].
21. Ceci G, Bella M, Melissari M, Gabrielli M, Bocchi P, Cocconi G. Fatal hepatic vascular toxicity of DTIC: is it really a rare event? Cancer 1988, 61, 1988-91.
22. Chabner BA, Amrein PC, Druker BJ, et al. Antineoplastic agents. In Goodman & Gilman's The Pharmacological Basis of Therapeutics, 11th edn, edited by. Laurence L. Brunton, John S. Lazo and Keith L. Parker. McGraw Hill, New York, NY, 2006, pp 1315-35.
23. Chan J, Loizzi V, Manetta A, Berman M. Oral altretamine used as salvage therapy in recurrent ovarian cancer. Gynecol Oncol 2004, 92, 368-71.
24. Chen CC, Taniguchi T, D'Andrea A. The Fanconi anemia (FA) pathway confers glioma resistance to DNA alkylating agents. J MolMed 2007, 85, 497-509.
25. Choi IS, Lee SH, Kim TY, et al. Phase II study of chemotherapy with ACNU plus cisplatin followed by cranial irradiation in patients with newly diagnosed glioblastoma multiforme. J Neurooncol 2002, 60, 171-6.
26. Cyclophosphamide AHFS Drug information, Bethesda, MD: American Society of Health-System Pharmacists. Electronic version 2007. Available from http://www.ashp.org/ahfs/firstrel/PDF/cyclophosphamideessential.pdf [accessed 2 October 2007].
27. Cyclophosphamide BC Cancer Agency. The Cancer Drug Manual©, Vancouver. Available from http://www.bccancer.bc.ca/NR/rdonlyres/37BE9D9E-8E5A-48C2-ABA1-953637C4A5C0/19503/yclophosphamideMonograph2Nov06.pdf [accessed 25 April 2008].
28. Dacarbazine Mayne Pharma (Canada) Inc. DACARBAZINE FOR INJECTION product monograph. Montreal, Quebec; 25 July 2003.
29. De Vita VT. A selective history of the therapy of Hodgkin's disease. Br J Haematol 2003, 122, 718-27.
30. Diehl V, Sieber M, Rüffer U, et al. BEACOPP: An intensified chemotherapy regimen in advanced Hodgkin's disease. Ann Oncol 1997, 8, 143-48.
31. Dinnes J, Cave C, Huang S, Major K,Milne R. The effectiveness and cost-efectiveness of temozolomide for the treatment of recurrent malignant glioma. Draft report to NICE, Wessex, Institute of Health Research and Development, 2000.
32. Dunn DL, Lubet RA, Prough RA. Oxidative metabolism of N-isopropyl-α-(2-methylhydrazino)-ptoluamide hydrochloride (Procarbazine) by rat liver microsomes. Cancer Res 1979, 39, 4555-63.
33. Dyke JP, Sanelli PC, Voss HU, et al. Monitoring the effects of BCNU chemotherapy Wafers (Gliadel) in glioblastoma multiforme with proton magnetic resonance spectroscopic imaging at 3.0 Tesla. J Neurooncol 2007, 82, 103-10.
34. Efthimiou M, Andriaanopoulos C, et al. Aneugenic potential of the nitrogen mustards analogues melphalan, chlorambucil and p-N,N-bis(2-chloroethyl)aminophenylacetic acid in cell cultures in vitro. Mutat Res 2007, 617, 125-37.
35. Eggermont AMM, Kirkwood JM. Re-evaluating the role of dacarbazine in metastatic melanoma: what have we learned in 30Years? Eur J Cancer, 2004, 40, 1825-36.
36. Evans JS, Gerritsen GC, Mann KM, Owen SP. Antitumor and hyperglycemic activity of streptozotocin (NSC-37917) and its cofactor, U-15,774. Cancer Chemother Rep 1965, 48, 1-6.
37. Everett, JL, Roberts, JJ, Ross, WCJ. Aryl-2-halogenoalkylamines. XII. Some carboxylic derivatives of N,N-Di-2-chloroethylaniline. J. Chem. Soc., 1953, 3, 2386-92.
38. FDA Matulane - U.S. Food and Drug Administration. Matulane label. http://www.accessdata.fda.gov/scripts/cder/onctools/labels.cfm?GN=procarbazine [accessed in 6 June 2008]
39. Finch RA, Shyam K, Penketh PG, Sartorelli AC. 1,2-Bis(methylsulfonyl)-1-(2-chloroethyl)-2-(methylamino)carbonylhydrazine (101M): a novel sulfonylhydrazine prodrug with broad-spectrum antineoplastic activity. Cancer Res 2001, 61, 3033-8.
40. Friedman HS, Kerby T, Calvert H. Temozolomide and treatment of malignant glioma. Clin Cancer Res 2000, 6, 2585-97.
41. Friedman HS, McLendon RE, Kerby T, et al. DNA mismatch repair and O6-alkylguanine-DNA alkyltransferase analysis and response to Temodal in newly diagnosed malignant glioma. J Clin Oncol 1998, 16, 3851-7.
42. Gajewski TF, Sosman J, Gerson SL, Liu L, Dolan E, Lin S, Vokes EE. Phase II trial of the O6-alkylguanine DNA alkyltransferase inhibitor O6-benzylguanine and 1,3-bis(2-chloroethyl)-1-nitrosourea in advanced melanoma. Clin Cancer Res 2005, 11, 7861-5.
43. Gardner ML and Martingano EC. Pediatric solid tumors of childhood. In: In Textbook of Therapeutics:Drug and Disease Management, 6th edn, edited by Herfindal ET, Gourley DR, Williams & Wilkins, Baltimore, 1996, p 1625.
44. Gerson SL. Clinical relevance of MGMT in the treatment of cancer. J Clin Oncol 2002, 20, 2388-99.
45. Gill RD, Cussac C, Souhami RL, Laval F. Increased Resistence to N, N0, N00-triethylenethiophosphoramide (thiotepa) in cells expressing the Escherichia coli formamidopyrimidine-DNA glycosylase. Cancer Res 1996, 56, 3721-4.
46. Gnewuch CT, Sosnovsky G. A critical appraisal of the evolution of N-nitrosoureas as anticancer drugs. Chem Rev 1997, 97, 829-1014.
47. Godeneche D, Rapp M, Thierry A, Laval F, Madelmont JC, Chollet P, Veyre A. DNA damage induced by a new 2-chloroethyl nitrosourea on malignant melanoma cells. Cancer Res 1990, 50, 5898-903.
48. Groninger E, Proost JH, de Graaf SSN. Pharmacokinetic studies in children with cancer. Crit Rev Oncol/Hematol 2004, 52, 173-97.
49. Grootenboers M, Heeren J, Putte B, et al. Isolated lung perfusion for pulmonary metastases, a review and work in progress. Perfusion 2006, 21, 267-76.
50. Gwak HS, Youn SM, Kwon AH, Lee SH, Kim JH, Rhee CH. ACNU-cisplatin continuous infusion chemotherapy as salvage therapy for recurrent glioblastomas: phase II study. J Neurooncol 2005, 75, 173-80.
51. Huitema AD, Spaander M, Mathjt RA, Tibben MM, Holtkamp MJ, Beijnen JH, Rodenhuis S. Relationship between exposure and toxicity in high-dose chemotherapy with cyclophosphamide, thiotepa and carboplatin. Ann Oncol 2002, 13, 374-84.
52. Ifosfamide BC Cancer Agency. The Cancer Drug Manual©, Vancouver. Available from http://www.bccancer.bc.ca/NR/rdonlyres/3EA37D74-6C87-4AD3-AFFC-8E93E0995DFB/21354/
53. Iggo N, Littlewood T,Winearls CG. Prospects for effective treatment of AL amyloidosis? Q J Med 2000, 93, 257-60.
54. Imbesi F, Marchioni E, Benericetti E, Zappoli F, Galli A, Corato M, Ceroni M. A randomized phase III study: comparison between intravenous and intraarterial ACNU administration in newly diagnosed primary glioblastomas. Anticancer Res 2006, 26, 553-8.
55. Ishiguro K, Seow HA, Penketh PG, Shyam K, Sartorelli AC. Mode of action of the chloroethylating and carbamoylating moieties of the prodrug cloretazine. Mol Cancer Ther 2006, 5, 969-76.
56. Keldsen N, Havsteen H, Vergote I, Bertelsen K, Jakobsen A. Altretamine (hexamethylmelamine) in the treatment of platinum-resistant ovarian cancer: a phase II study. Gynecol Oncol 2003, 88, 118-22.
57. Kim YH, Martinez G, Varghese A, Hoppe RT. Topical nitrogen mustard in the management of mycosis fungoides. Arch Dermatol 2003, 139, 165-73.
58. Larkin JM, Hughes SA, Beirne DA, et al. A phase I/II study of lomustine and temozolomide in patients with cerebral metastases from malignant melanoma. Br J Cancer 2007, 96, 44-8.
59. Lawson HC, Sampath P, Bohan E, et al. Interstitial chemotherapy for malignant gliomas: the Johns Hopkin experience. J Neurooncol 2007, 83, 61-70.
60. Lemoine A, Lucas C, Ings RM. Metabolism of the chloroethylnitrosoureas. Xenobiotica 1991, 21, 775-91.
61. Lin K-H, Lin D-T, Jou S-T, Lu M-Y, Chang Y-H, Tien H-F. Forty-seven children suffering from chronic myeloid leukemia at a center over a 25-year period. Pediatr Hematol Oncol 2003, 20, 505-15.
62. Lister TA, Cullen MH, Beard ME, et al. Comparison of combined and single-agent chemotherapy in non-Hodgkin's lymphoma of favourable histological type. BMJ 1978, 1, 533-7.
63. Lomustine AHFS Drug information, Bethesda, MD:American Society of Health-System Pharmacists.Electronic version 2007. Available from http://www.medecinescomplete.com/. [accessed 19 July 2007].
64. Lomustine BC Cancer Available from htpp://bccancer.bc.ca/HPI/DrugDatabase/DrugIndexPro/lomustine.htm. [accessed 27 July 2007].
65. Lown JW, Chauhan SM. Mechanism of action of (2-haloethyl)nitrosoureas on DNA. Isolation and reactions of postulated 2-(alkylimino)-3-nitrosooxazolidine intermediates in the decomposition of 1,3-bis(2-chloroethyl)-, 1-(2-chloroethyl)-3-cyclohexyl-, and 1-(2-chloroethyl)-3-(40-transmethylcyclohexyl)-1-nitrosourea. J Med Chem 1981, 24, 270-9.
66. Madelmont JC, Godeneche D, Parry D, Duprat J, Chabard JL, Plagne R, Mathe G,Meyniel G. New cysteamine (2-chloroethyl)nitrosoureas. Synthesis and preliminary antitumor results. J Med Chem 1985, 28, 1346-50.
67. Malik I. Altretamine is an effective palliative therapy of patients with recurrent epithelial ovarian cancer. Jpn J Clin Oncol 2001, 31, 69-73.
68. Massoud M, Armand JP, Ribrag V. Procarbazine in haematology: an old drug with a new life? Eur J Cancer 2004, 40, 1924-7.
69. Masta A, Gray PJ, Philips R. Molecular basis of nitrogen mustards effects on transcription processes:role of depurination. Nucl Acids Res 1994, 22, 3880-6.
70. Matulane - Sigma-tau Pharmaceuticals, Inc., Gaithersburg,MD 20877 (Revised: February 2004). Available from http://www.matulane.com/pdf/prescribe-info.pdf. [accessed 17 October 2007].
71. McCormick JE, McElhinney RS. Nitrosoureas from chemist to physician: classification and recent approaches to drug design. Eur J Cancer 1990, 26, 207-21.
72. McEvoy GK. American Hospital Formulary Service: drug information 2007/ed. American Society of Health-System Pharmacists, Bethesda: ASHSP, 2007, pp 953-8.
73. Merlini G. Refining therapy for AL amyloidosis. Blood 2006, 108, 3632-3.
74. Middleton M, Grob J, Aaronson N, et al. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol 2000, 18, 158-66.
75. Middleton M, Jonas DL, Kiebert GM. Health-related quality of life in patients with advanced metastatic melanoma: results of a randomized phase III study comparing temozolomide with dacarbazine. Cancer Investig, 2003, 6, 821-9.
76. Mishina Y, Duguid EM, He C. Direct reversal of DNA alkylation damage. Chem Rev 2006, 106, 215-32.
77. Moloney SJ, Wiebkin P, Cummings SW, Prough RA. Metabolic activation of the terminal N-methyl group of N-isopropyl-α-(2-methylhydrazino)-p-toluamide hydrochloride (procarbazine). Carcinogenesis 1985, 6, 397-401.
78. Morimoto M, Green D, Rahman A, Goldin A, Schein S. Comparative pharmacology of pentamethylmelamine and Hexamethylmelamine in Mice. Cancer Res 1980, 40, 2762-7.
79. Myleran®, Glaxo Smith Kline I. Myleran product monograph. Research Triangle Park, North Carolina, 2003.
80. NCI/clinical trials. Available from htpp://nciterms.nci.nih.gov/. [accessed 26 July 2007].
81. Newlands ES, Stevens MFG, Wedge SR, Wheelhouse RT, Brock C. Temozolomide: a review of its discovery, chemical properties, pre-clinical development and clinical trials. Cancer Treat Rev 1997, 23, 35-61.
82. NHS Cancer Network. Available from http://www.swshcn.nhs.uk/healthcare-professionals/clinicalpolicies-and-protocols/haematologyprotocols/myeloproliferative-dysplastic-disorders/Busulfan%20V1%204.06.pdf [accessed in 6 June 2008]
83. Nicolle A, Proctor SJ, Summerfield GP. High dose chlorambucil in the treatment of lymphoid malignancies. Leuk Lymphoma 2004, 45, 271-5.
84. Ogawa K, Yoshii Y, Toita T, et al. Hyperfractionated radiotherapy and multi-agent chemotherapy (procarbazine, ACNU and vincristine) for high-grade gliomas: a prospective study. Anticancer Res 2006, 26, 2457-62.
85. Ohnishi K, Ohno R, Tomonaga M, et al. A randomized trial comparing Interferon-α with busulfan for newly diagnosed chronic myelogenous leukemia in chronic phase. Blood 1995, 86, 906-16.
86. Oken MM, Lee S, Kay NE, Knospe W, Cassileth PA. Pentostatin. chlorambucil and prednisone therapy for b-chronic lymphocytic leukemia: a phase I/II study by the Eastern Cooperative Oncology Group Study E1488. Leuk Lymphoma 2004, 45, 79-84.
87. Palumbo A, Giaccone L, Bertola A. Low-dose thalidomide plus dexamethasone is an effective salvage therapy for advanced myeloma. Haematologica 2002, 86, 399-403.
88. Papac RJ. Origins of cancer therapy. Yale J Biol Med 2001, 74, 391-8.
89. Passagne I, Evrard A, Winum JY, Depeille P, Cuq P, Montero JL, Cupissol D, Vian L. Cytotoxicity, DNA damage, and apoptosis induced by new fotemustine analogs on human melanoma cells in relation to O6-methylguanine DNA-methyltransferase expression. J Pharmacol Exp Ther, 2003, 307, 816-23.
90. Pinguet F, Culine S, Bressolle F, Astre C, Serre MP, Chevillard C, Fabbro M. A Phase I and pharmacokinetic study of melphalan using a 24-hour contìnuos infusion in patients with advanced malignancies. Clin Cancer Res 2000, 6, 57-63.
91. Pletsa V, Valavanis C, van Delft HM, Steenwinkel M-J ST, Kyrtopoulos SA. DNA damage and mutagenesis induced by procarbazine in λlacZ transgenic mice: Evidence that bone marrow mutations do not arise primarily trough miscoding by O6-methylguanine. Carcinogenesis 1997, 11, 2191-6.
92. Ponisch W, Mitrou P, Merkle K, et al. Multicentric prospective randomized trial of bendamustine/ prednisone versus melphalan/prednisone in 136 patients with multiple myeloma. Proc Am Soc Clin Oncol 2000; 19: 9a (Abstr 25).
93. Procarbazine BC Cancer Agency Drug. The Cancer Drug Manual©]. Vancouver. Available from http://www.bccancer.bc.ca/NR/rdonlyres/7B97C0C8-FFF9-4317-8397-81E6268746A9/19521/Procarbazinemonograph3Nov06.pdf. [accessed 10 October 2007].
94. Rabik CA, Njoku MC, Dolan ME. Inactivation of O6-alkylguanine DNA alkyltransferase as a means to enhance chemotherapy. Cancer Treat Rev 2006, 32, 261-76.
95. Remington. The Science and Practice of Pharmacy, 21st edn. LippincottWilliams&Wilkins, Baltimore, 2005, Chapter 86, p 1580. Scholtz JM (Chapter author); Hendrickson R (Editor)
96. Rigacci L, Carrai V, Nassi L, Alterini R, Longo G, Bernardi F, Bosi A. Combined chemotherapy with carmustine, doxorubicin, etoposide, vincristine, and cyclophosphamide plus mitoxantrone, cytarabine and methotrexate with citrovorum factor for the treatment of aggressive non-Hodgkin lymphoma: a long-term follow-up study. Cancer 2005, 103, 970-7.
97. Roche H, Cure H, Adenis A, Fargeot P, Terret C, Lentz MA, Madelmont JC, Fumoleau P, Hanausk A, Chollet P. Phase II trial of cystemustine, a new nitrosourea, as treatment of high-grade brain tumors in adults. J Neurooncol 2000, 49, 141-5.
98. Rubia J de la, Blade J, Lahuerta JJ, et al. Effect of chemotherapy with alkylating agents on the yield of CD34+ cells in patients with multiple myeloma. Results of the Spanish Myeloma Group (GEM) Study. Haematologica, 2006, 91, 621-7.
99. Ryan CW, Dolan ME, Brockstein BB, McLendon R, Delaney SM, Samuels BL, Agamah ES, Vokes EE. A phase II trial of O6-benzylguanine and carmustine in patients with advanced soft tissue sarcoma. Cancer Chemother Pharmacol 2006, 58, 634-9.
100. Sanchorawala V,Wright D, Seldin D, et al. An overview of the use of high-dose melphalan with autologous stem cell transplantation for the treatment of AL amyloidosis. Bone Marrow Transpl 2001, 28, 637-42.
101. Sanderson BJ, Shield AJ. Mutagenic damage tomammalian cells by therapeutic alkylating agents. Mutat Res 1996, 355, 41-57.
102. Schabel FM Jr. Nitrosoureas: a review of experimental antitumor activity. Cancer Treat Rep 1976, 60, 665-98.
103. Schein PS, O'Connell MJ, Blom J, et al. Clinical antitumor activity and toxicity of streptozotocin (NSC-85998). Cancer 1974, 34, 993-1000.
104. Schwanen C, Hecker T, Hubinger G, Rittgen W, Bergmann L, Karakas T. In vitroevaluation of bendamustine induced apoptosis in B-chronic lymphocytic leukemia. Leukemia 2002, 16, 2096-105.
105. Silvennoinen R, Malminiemi K, Maliminiemi O, Seppala E, Vilpo J. Pharmacokinetics of chlorambucil in patients with chronic lymphocytic leukaemia: comparison of different days, cycles, doses. Pharmacol Toxicol 2000, 87, 223-8.
106. Silver RT, Woolf SH, Hehlmann R, et al. An evidence based analysis of the effect of busulfan, hydroxyurea, interferon and allogeneic bone marrow transplantation in treating the chronic phase of chronic myeloid leukemia: developed for the American Society of Hematology. Blood 1999, 94, 1517-36.
107. Silverman, R. The Organic Chemistry of Drug Design and Drug Action. Academic Press, San Diego, 2004, pp 353-68.
108. Slattery JT, Gibbs JP, McCune JS. Plasma concentration monitoring of busulfan. Clin Pharmacokin 2000, 39, 155-65.
109. Smith ML, Newland AC. Treatment of myeloma. Q J Med 1999, 92, 11-14.
110. Soloway MS, Ford KS. Thiotepa-induced myelosupression: review of 670 bladder instillations. J Urol 1983, 130, 889-91.
111. Stewart DA, Bahlis N, Valentine K, et al. Upfront double high-dose chemotherapy with DICEP followed by BEAM and autologous stem cell transplantation for poor-prognosis aggressive non-Hodgkin lymphoma. Blood 2006, 107, 4623-7.
112. Streptozocin AHFS Drug information, Bethesda, MD: American Society of Health-System Pharmacists. Electronic version 2007. Available from http://www.medecinescomplete.com/. [accessed 19 July 2007].
113. Sugiyama S, Yamashita Y, Kikuchi T, Saito R, Kumabe T, Tominaga T. Safety and efficacy of convection-enhanced delivery of ACNU, a hydrophilic nitrosourea, in intracranial brain tumor models. J Neurooncol, 2007, 82, 41-7.
114. Sweetman SC (ed.) Martindale: The Complete Drug Reference. Pharmaceutical Press, London. Electronic version, September 2007.
115. Webster M, Cairncross G, Gertler S, Perry J, Wainman N, Eisenhauer E. Phase II trial of SarCNU in malignant glioma: unexpected pulmonary toxicity with a novel nitrosourea: a phase II trial of the national cancer institute of canada clinical trials group. Invest New Drugs 2005, 23, 591-6.
116. Weidmann E, Kim S-Z, Rost A, et al. Bendamustine is effective in relapsed or refractory aggressive non-Hodgkin's lymphoma. Ann Oncol 2002, 13, 1285-9.
117. Wong RP, Baetz T, Krahn MJ, Biagi J, Wainman N, Eisenhauer E. National Cancer Institute of Canada Clinical Trials Group. SarCNU in recurrent or metastatic colorectal cancer: a phase II study of the National Cancer Institute of Canada Clinical Trials Group. Invest New Drugs 2006, 24, 347-51.
118. Zhang J, Tian Q, Zhou S-F. Clinical pharmacoplogy of cyclophosphamide and ifosfamide. Curr Drug Ther 2006, 1, 55-84.